Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Cardiome Selects Quintiles To Manage Global Regulatory Affairs And Life Cycle Safety Activities For BRINAVESS™



Cardiome Selects Quintiles To Manage Global Regulatory Affairs And Life Cycle
          Safety Activities For BRINAVESS™ (Vernakalant Intravenous)

PR Newswire

VANCOUVER, Feb. 4, 2013

NASDAQ: CRME   TSX: COM

VANCOUVER, Feb. 4, 2013 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: CRME /
TSX: COM) today announced the selection of Quintiles to provide comprehensive
post-marketing lifecycle safety and global regulatory affairs services for
BRINAVESS™. Quintiles, the world's leading provider of biopharmaceutical
services, will begin providing these services effective immediately as
Cardiome continues to prepare for the anticipated transfer of BRINAVESS^TM
from Merck to Cardiome.

"We are very pleased to begin our partnership with Quintiles during the
pending return of global rights for the intravenous (IV) and oral formulations
of vernakalant to Cardiome," stated William Hunter, M.D., interim CEO of
Cardiome. "Finding a highly capable service provider to deliver operational
regulatory and pharmacovigilance support was a key priority to effectively and
expeditiously transfer the registered marketing authorizations from Merck to
Cardiome.  We believe that Quintiles' global reach and extensive expertise in
these areas will help facilitate a seamless worldwide transition."

In September 2012, Merck informed Cardiome that Merck (through two of its
subsidiaries) would return the global marketing and development rights for
both the intravenous and oral formulations of vernakalant to Cardiome.
Vernakalant IV is marketed under the brand name BRINAVESS^TM. BRINAVESS^TM has
received approval in the European Union and certain other markets worldwide
for the rapid conversion of recent onset atrial fibrillation (AF) to sinus
rhythm in adults: for non-surgery patients with AF of seven days or less and
for post-cardiac surgery patients with AF of three days or less. Vernakalant
IV is not approved for use in the United States or Canada.

About Cardiome Pharma Corp. Cardiome Pharma Corp. is a biopharmaceutical
company dedicated to the discovery, development and commercialization of new
therapies that will improve the health of patients around the world. Cardiome
has one marketed product, BRINAVESS™ (vernakalant IV), approved in Europe and
other territories for the rapid conversion of recent onset atrial fibrillation
to sinus rhythm in adults.

Cardiome is traded on the NASDAQ Capital Market (CRME) and the Toronto Stock
Exchange (COM). For more information, please visit our web site at
www.cardiome.com.

Forward-Looking Statement Disclaimer

Certain statements in this press release contain forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995 or
forward-looking information under applicable Canadian securities legislation
that may not be based on historical fact, including without limitation
statements containing the words "believe", "may", "plan", "will", "estimate",
"continue", "anticipate", "intend", "expect" and similar expressions. Such
forward-looking statements or information involve known and unknown risks,
uncertainties and other factors that may cause our actual results, events or
developments, or industry results, to be materially different from any future
results, events or developments expressed or implied by such forward-looking
statements or information. Risks, uncertainties and factors that could cause
such actual events or results expressed or implied by such forward-looking
statements and information to differ materially from any future events or
results expressed or implied by such statements and information include, but
are not limited to, the risks, uncertainties and factors related to the fact
that: we, together with our collaborative partner, may not be able to
successfully develop all or any of our current or future products and may not
be able to obtain regulatory approval in targeted indications for our current
or future products in all markets; we may not achieve or maintain
profitability; our future operating results are uncertain and likely to
fluctuate; we may not be able to raise additional capital as and when
required; we depend on our collaborative partner to perform their obligations
under licensing or other collaborative agreements; we may not be successful in
establishing additional corporate collaborations or licensing arrangements; we
may not be able to establish marketing and sales capabilities and the costs of
launching our products may be greater than anticipated; any of our products
that obtain regulatory approval will be subject to extensive post-market
regulation that may affect sales, marketing and profitability; any of our
products that are successfully developed may not achieve market acceptance; we
rely on third parties for the continued supply and manufacture of our products
and have no experience in commercial manufacturing; we may face unknown risks
related to intellectual property matters, including with respect to our
ability to protect our intellectual property; we face increased competition
from pharmaceutical and biotechnology companies; and other factors as
described in detail in our filings with the Securities and Exchange Commission
available at www.sec.gov and the Canadian securities regulatory authorities at
www.sedar.com.  Given these risks, uncertainties and factors, you are
cautioned not to place undue reliance on such forward-looking statements and
information, which are qualified in their entirety by this cautionary
statement. All forward-looking statements and information made herein are
based on our current expectations and we undertake no obligation to revise or
update such forward-looking statements and information to reflect subsequent
events or circumstances, except as required by law.

SOURCE Cardiome Pharma Corp.

Contact:

Cardiome Investor Relations
(604) 676-6993 or Toll Free: 1-800-330-9928
Email: ir@cardiome.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement